Table 2.
Some nanoparticle-based SARS-CoV-2 vaccines that are in phase-4, phase-3 of clinical trials or have qualified for WHO Emergency use authorization [94,108].
| Sr. No. |
Vaccine Name |
Type of vaccine |
Developer |
Registered Trial Number (s) |
|---|---|---|---|---|
| WHO-EUA qualified COVID-19 vaccines | ||||
| 1 | Covilo | Inactivated Virus | Sinopharm | NCT05204589; NCT04984408; NCT04560881; NCT04917523; NCT04612972; ChiCTR2000034780; IRCT20201214049709N3; IRCT20210206050259N3 |
| 2 | CoronaVac | Sinovac | NCT04800133; NCT04582344; NCT04651790; NCT04992260; NCT04456595; NCT05156632; PHRR210210-003308; NCT05077176; NCT05137418; NCT05225285; NCT04617483; NCT04508075, 669/UN6.KEP/EC/2020; NCT05204589 | |
| 3 | Covaxin | Bharat Biotech | CTRI/2020/11/028976, NCT04641481; NCT04918797 | |
| 4 | Ad26.COV2.S | Non-replicating viral vector | Janssen (Johnson & Johnson) | NCT05220397; NCT05148845; NCT05048940; NCT05047640; NCT05091307; NCT04505722; NCT04838795, PACTR202102855526180; NCT04614948, ISRCTN14722499 |
| 5 | Vaxzevria | Oxford/AstraZeneca | NCT04540393; ISRCTN89951424, NCT04536051; NCT04864561; NCT05007951; NCT04516746; EUCTR2020-001228-32, NCT04400838; CTRI/2020/08/027170; NCT05059106; NCT05236491; NCT04756271; NCT05011526; NCT04885764; NCT05198596; NCT04800133; NCT05017792 | |
| 6 | Covishield | Serum Institute of India | CTRI/2020/08/027170 | |
| 7 | Comirnaty | mRNA | Pfizer/BioNTech | NCT05124171, EUCTR2021-004550-33; jRCT2071210106; NCT05022329; NCT04805125; NCT05142319; NCT05228730; NCT04368728, EUCTR2020-002641-42; NCT05225285; NCT05047640; NCT04754594; NCT04816669; EUCTR2020-005442-42; NCT04951323; NCT04713553; NCT05029245; NCT04800133 |
| 8 | Spikevax | Moderna | NCT04806113; NCT04860297; NCT04811664; NCT05168813; NCT05236491; NCT05048940; NCT04470427; NCT04927065; NCT05249829; NCT04805125; jRCT2071210106; NCT05230953; NCT05228730; NCT05022329; NCT05119855; NCT05142319; NCT05158140; NCT04649151; NCT04796896 | |
| 9 | Nuvaxovid | Protein subunit | Novavax | EUCTR2020-004123-16, NCT04583995; CTRI/2021/02/031554; NCT05236491; NCT04611802 |
| 10 | Covovax | Serum Institute of India: | CTRI/2021/02/031554 | |
| Phase 4 | ||||
| 11 | Covilo | Inactivated Virus | Sinopharm | NCT04863638; NCT05105295; NCT05104216 |
| 12 | CoronaVac | Sinovac | NCT04756830; NCT04747821; NCT04775069; NCT04789356; NCT04754698; NCT04801888; NCT04911790; NCT04953325; NCT04962308; NCT05057169; | |
| 13 | Ad5-nCoV-IH | Non-Replicating Viral Vector | CanSino | NCT04892459 |
| 14 | Ad26.COV2.S | Janssen (Johnson & Johnson) | NCT05057169; NCT05037266; NCT05030974 | |
| 15 | Vaxzevria | Oxford/AstraZeneca | NCT04775069; NCT04760132; NCT04914832 | |
| 16 | Comirnaty | mRNA | Pfizer/BioNTech | NCT04775069; NCT04760132; NCT04969250; NCT04780659; NCT05057182; NCT05047718; NCT04955626; NCT04952766 |
| 17 | Spikevax | Moderna | NCT04760132; NCT05030974; NCT04792567; NCT05047718; NCT04952402; NCT04885907; NCT04969250 | |
| Phase 3 | ||||
| 18 | Nanocovax | Protein subunit | Nanogen Pharma | NCT04922788 |
| 19 | Zifivax | Anhui ZhifeiLongcom | ChiCTR2100050849; NCT05107375; ChiCTR2000040153, NCT04646590; NCT05091411; NCT05128643 | |
| 20 | MVC-COV1901 | Medigen Vaccine Biologics Corporation | NCT05198596; NCT05011526 | |
| 21 | V-01 | Livzon Mabpharm Inc | NCT05096845; NCT05096832 | |
| 22 | ReCOV | Jiangsu Rec-Biotechnology Co Ltd: | NCT05084989 | |
| 23 | RaziCov Pars | Razi Vaccine and Serum Research Institute | IRCT20201214049709N3 | |
| 24 | Recombinant Protein | Sanofi/GSK | NCT04904549; PACTR202011523101903 | |
| 25 | Soberana Plus | Instituto Finlay de Vacunas Cuba | IFV/COR/09 | |
| 26 | SP/GSK subunit B.1.351 vaccine | Sanofi/GSK | NCT05124171, EUCTR2021-004550-33 | |
| 27 | SCTV01C | Sinocelltech | NCT05043285; NCT05043311 | |
| 28 | S-268019 | Shionogi | NCT05212948; jRCT2031210383 | |
| 29 | GBP510 | SK Bioscience Co Ltd | NCT05007951 | |
| 30 | UB-612 | Vaxxinity/DASA | NCT04683224 | |
| 31 | SCB-2019 | Clover Biopharmaceuticals | NCT04672395; NCT05188677; PHRR210209-003334; NCT05193279 | |
| 32 | AKS-452 | University Medical Center Groningen | CTRI/2021/10/037269 | |
| 33 | Abdala | Center for Genetic Engineering and Biotechnology (CIGB) | RPCEC00000359 | |
| 34 | SpikoGen | Vaxine/CinnaGen Co. | NCT05175625, IRCT20150303021315N26; NCT05148871; NCT05005559, IRCT20150303021315N24 | |
| 35 | EpiVacCorona | Vector State Research Center of Virology and Biotechnology | NCT05021016; NCT04780035 | |
| 36 | Corbevax | Biological E Limited | CTRI/2021/10/037066; CTRI/2021/08/036074; CTRI/2021/06/034014 | |
| 37 | Recombinant (Sf9 cell) | West China Hospital | NCT04904471; NCT04887207 | |
| 38 | Noora vaccine | Bagheiat-allah University of Medical Sciences | IRCT20210620051639N3 | |
| 39 | Recombinant SARS-CoV-2 Vaccine (CHO Cell) | National Vaccine and Serum Institute | NCT05069129 | |
| 40 | Covifenz | Virus like particles | Medicago | NCT05040789; NCT04636697 |
| 41 | LYB001 | Yantai Patronus Biotech Co Ltd | NCT05137444 | |
| 42 | AG0302-COVID19 | DNA | AnGes | NCT04655625 |
| 43 | ZyCoV-D | Zydus Cadila | CTRI/2021/01/030416 | |
| 44 | INO-4800 | Inovio | NCT04642638; PACTR202110626944896 | |
| 45 | GX-19 | Genexine | NCT05067946 | |
| 46 | BNT162b2s01 | mRNA | Pfizer/BioNTech | NCT04368728, EUCTR2020-002641-42 |
| 47 | ARCT-154 | Arcturus Therapeutics Inc | NCT05012943 | |
| 48 | DS-5670a | Daiichi Sankyo Co Ltd | jRCT2071210106 | |
| 49 | mRNA-1273.529 | Moderna | NCT05249829 | |
| 50 | GRAd-COV2 | Non-Replicating Viral Vector | ReiThera | NCT04791423; EUCTR2020-005915-39 |
| 51 | AZD2816 | Oxford/AstraZeneca | NCT04973449 | |
| 52 | Sputnik Light | Gamaleya | NCT04741061 | |
| 53 | Convidecia | CanSino | NCT04540419; NCT05169008; NCT04526990 | |
| 54 | Sputnik V | Gamaleya | NCT04656613; NCT04530396; NCT04640233; NCT04642339; NCT04564716; NCT04954092 | |
| 55 | Ad5-nCoV-IH | CanSino | NCT05204589; NCT05169008; NCT05124561 | |
| 56 | Brilife | Replicating Viral Vector | Israel Institute for Biological Research (IIBR) | NCT04990466 |
| 57 | DelNS1-2019-nCoV-RBD-OPT1 | WantaiBioPharm | ChiCTR2100051391; PACTR202110872285345 | |
| 58 | Turkovac | Inactivated virus | Health Institutes of Turkey | NCT04942405; NCT05077176 |
| 59 | VLA2001 | Valneva SE | NCT04956224; NCT04864561 | |
| 60 | COVIranBarekat | Shifa Pharmed Industrial Co | IRCT20201202049567N3 | |
| 61 | KCONVAC | Minhai Biotechnology Co | NCT05204589; NCT04852705 | |